193 related articles for article (PubMed ID: 10096544)
61. Heterologous prime-boost immunizations with a virosomal and an alphavirus replicon vaccine.
Walczak M; de Mare A; Riezebos-Brilman A; Regts J; Hoogeboom BN; Visser JT; Fiedler M; Jansen-Dürr P; van der Zee AG; Nijman HW; Wilschut J; Daemen T
Mol Pharm; 2011 Feb; 8(1):65-77. PubMed ID: 20825215
[TBL] [Abstract][Full Text] [Related]
62. CD4-positive and CD8-positive cytotoxic T lymphocytes contribute to human papillomavirus type 16 E6 and E7 responses.
Nakagawa M; Stites DP; Palefsky JM; Kneass Z; Moscicki AB
Clin Diagn Lab Immunol; 1999 Jul; 6(4):494-8. PubMed ID: 10391849
[TBL] [Abstract][Full Text] [Related]
63. Immunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects.
Indrová M; Reinis M; Bubeník J; Jandlová T; Bieblová J; Vonka V; Velek J
Folia Biol (Praha); 2004; 50(6):184-93. PubMed ID: 15709713
[TBL] [Abstract][Full Text] [Related]
64. Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice.
Qian J; Dong Y; Pang YY; Ibrahim R; Berzofsky JA; Schiller JT; Khleif SN
Int J Cancer; 2006 Jun; 118(12):3022-9. PubMed ID: 16425257
[TBL] [Abstract][Full Text] [Related]
65. Identification of novel immunogenic human leukocyte antigen-A 2402-binding epitopes of human papillomavirus type 16 E7 for immunotherapy against human cervical cancer.
Jang S; Kim YT; Chung HW; Lee KR; Lim JB; Lee K
Cancer; 2012 Apr; 118(8):2173-83. PubMed ID: 21918960
[TBL] [Abstract][Full Text] [Related]
66. Development of a Human Cytomegalovirus (HCMV)-Based Therapeutic Cancer Vaccine Uncovers a Previously Unsuspected Viral Block of MHC Class I Antigen Presentation.
Abdelaziz MO; Ossmann S; Kaufmann AM; Leitner J; Steinberger P; Willimsky G; Raftery MJ; Schönrich G
Front Immunol; 2019; 10():1776. PubMed ID: 31417555
[TBL] [Abstract][Full Text] [Related]
67. [Preparation of HPV18 E7 peptide plus CpG vaccine and its immunologic effects in vitro].
Liao SJ; Zhang WN; Hu XJ; Jiang XF; Wang CY; Lu YP; Wang SX; Ma D
Zhonghua Yi Xue Za Zhi; 2012 Jun; 92(23):1641-5. PubMed ID: 22944136
[TBL] [Abstract][Full Text] [Related]
68. Evaluation of immunological cross-reactivity between clade A9 high-risk human papillomavirus types on the basis of E6-Specific CD4+ memory T cell responses.
van den Hende M; Redeker A; Kwappenberg KM; Franken KL; Drijfhout JW; Oostendorp J; Valentijn AR; Fathers LM; Welters MJ; Melief CJ; Kenter GG; van der Burg SH; Offringa R
J Infect Dis; 2010 Oct; 202(8):1200-11. PubMed ID: 20822453
[TBL] [Abstract][Full Text] [Related]
69. Toll like receptor agonists augment HPV 11 E7-specific T cell responses by modulating monocyte-derived dendritic cells.
Chen XZ; Mao XH; Zhu KJ; Jin N; Ye J; Cen JP; Zhou Q; Cheng H
Arch Dermatol Res; 2010 Jan; 302(1):57-65. PubMed ID: 19578865
[TBL] [Abstract][Full Text] [Related]
70. Induction of robust cellular immunity against HPV6 and HPV11 in mice by DNA vaccine encoding for E6/E7 antigen.
Shin TH; Pankhong P; Yan J; Khan AS; Sardesai NY; Weiner DB
Hum Vaccin Immunother; 2012 Apr; 8(4):470-8. PubMed ID: 22336879
[TBL] [Abstract][Full Text] [Related]
71. Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E7.
Oosterhuis K; Ohlschläger P; van den Berg JH; Toebes M; Gomez R; Schumacher TN; Haanen JB
Int J Cancer; 2011 Jul; 129(2):397-406. PubMed ID: 21207427
[TBL] [Abstract][Full Text] [Related]
72. Human papillomavirus 16-specific T cell responses in classic HPV-related vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins.
Bourgault Villada I; Moyal Barracco M; Berville S; Bafounta ML; Longvert C; Prémel V; Villefroy P; Jullian E; Clerici T; Paniel B; Maillère B; Choppin J; Guillet JG
Clin Exp Immunol; 2010 Jan; 159(1):45-56. PubMed ID: 19843089
[TBL] [Abstract][Full Text] [Related]
73. Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7.
Tsang KY; Fantini M; Fernando RI; Palena C; David JM; Hodge JW; Gabitzsch ES; Jones FR; Schlom J
Vaccine; 2017 May; 35(19):2605-2611. PubMed ID: 28389098
[TBL] [Abstract][Full Text] [Related]
74. T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx.
Hoffmann TK; Arsov C; Schirlau K; Bas M; Friebe-Hoffmann U; Klussmann JP; Scheckenbach K; Balz V; Bier H; Whiteside TL
Int J Cancer; 2006 Apr; 118(8):1984-91. PubMed ID: 16284959
[TBL] [Abstract][Full Text] [Related]
75. Enhanced Cytotoxic CD8 T Cell Priming Using Dendritic Cell-Expressing Human Papillomavirus-16 E6/E7-p16INK4 Fusion Protein with Sequenced Anti-Programmed Death-1.
Garcia-Bates TM; Kim E; Concha-Benavente F; Trivedi S; Mailliard RB; Gambotto A; Ferris RL
J Immunol; 2016 Mar; 196(6):2870-8. PubMed ID: 26851223
[TBL] [Abstract][Full Text] [Related]
76. Different methods of identifying new antigenic epitopes of human papillomavirus type 16 E6 and E7 proteins.
Nakagawa M; Kim KH; Moscicki AB
Clin Diagn Lab Immunol; 2004 Sep; 11(5):889-96. PubMed ID: 15358648
[TBL] [Abstract][Full Text] [Related]
77. Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations.
Cheng WF; Lee CN; Su YN; Chang MC; Hsiao WC; Chen CA; Hsieh CY
Immunology; 2005 May; 115(1):136-49. PubMed ID: 15819706
[TBL] [Abstract][Full Text] [Related]
78. Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro.
Rudolf MP; Fausch SC; Da Silva DM; Kast WM
J Immunol; 2001 May; 166(10):5917-24. PubMed ID: 11342606
[TBL] [Abstract][Full Text] [Related]
79. Identification in humans of HPV-16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA-B18 and determination of the HLA-B18-specific binding motif.
Bourgault Villada I; Bénéton N; Bony C; Connan F; Monsonego J; Bianchi A; Saiag P; Lévy JP; Guillet JG; Choppin J
Eur J Immunol; 2000 Aug; 30(8):2281-9. PubMed ID: 10940919
[TBL] [Abstract][Full Text] [Related]
80. The modification of Tapasin enhances cytotoxic T lymphocyte activity of intracellularly delivered CTL epitopes via cytoplasmic transduction peptide.
Chen X; Liu H; Tang Z; Yu Y; Zang G
Acta Biochim Biophys Sin (Shanghai); 2013 Mar; 45(3):203-12. PubMed ID: 23299079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
